Noxopharm Ltd
NOX
Company Profile
Business description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Contact
60 Linksley Avenue
GlenhavenNSW2156
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
17
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar analysts’ take on the takeover for this undervalued industrial player.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.00 | 31.90 | 0.36% |
| CAC 40 | 8,154.91 | 15.97 | 0.20% |
| DAX 40 | 25,578.85 | 3.84 | 0.02% |
| Dow JONES (US) | 51,872.94 | 175.89 | -0.34% |
| FTSE 100 | 10,708.33 | 30.68 | -0.29% |
| HKSE | 25,087.75 | 45.04 | 0.18% |
| NASDAQ | 27,249.60 | 127.51 | 0.47% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,875.48 | 54.28 | 0.39% |
| S&P 500 | 7,771.42 | 6.72 | 0.09% |
| S&P/ASX 200 | 8,757.80 | 25.90 | 0.30% |
| SSE Composite Index | 3,952.13 | 2.22 | 0.06% |